TRIMEDYNE’S CHAIRMAN SPEAKS TO THE INVESTMENT COMMUNITY ON WALLST.NET
30, 2004 – Irvine, CA: TRIMEDYNE, INC. (Symbol “TMED”)
today announced its Chairman, Marvin P. Loeb, described the
Company’s products, medical applications and financial results
in an audio interview on WallSt.Net.
recently reported its seventh consecutive quarterly profit.
It manufactures Holmium Lasers and Optical Fibers for
fragmenting stones in the kidney, ureter or bladder, and Laser
Needles for use in new, outpatient procedures to treat
herniated or ruptured discs in the spine.
our disc procedures, the patient’s back pain usually
disappears during or shortly after the approximate 20 to 40
minute procedure, and the patient typically walks out with only
a band-aid on the puncture, no stitches, and is back to light
activities in a few days. Surgery
to treat these conditions generally requires a two-to-seven day
hospital stay, a lengthy, recuperation period and a long absence
from work,” Loeb said.
estimated 10 million people in the United States suffer from
back pain, most often from a damaged or diseased spinal disc,”
hear the entire interview, visit www.wallst.net,
click on Audio Search and enter the TMED symbol.
The audio interview will be available for a month or
longer. For more information on Trimedyne, visit www.trimedyne.com.
owned and operated by Digital Wall Street, Inc., a multimedia
provider of original, insightful commentary and news from North
America’s leading companies. Giving
a direct link to the management of today’s fastest-growing
companies through executive interviews and sector seminars, www.wallst.net
provides a free service to consumers, and a paid, premium
monthly subscription to its members.
"Safe Harbor" Statement
Under the Private Securities Litigation Reform Act:
Statements in this news release and the audio interview
may contain forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1993 and Section 21E
of the Securities and Exchange Act of 1934.
Such statements may involve various risks and
uncertainties, some of which may be discussed in the Company's
most recent report on Form 10-KSB and subsequently filed SEC
reports. There is
no assurance any new products can be cleared for sale by the FDA
or successfully commercialized or any forward-looking statements
will prove accurate, as actual results and future events could
differ materially from those presently anticipated.